New York Patent of the Month – October 2023
Gameto, Inc. is a pioneering biotechnology company with a mission to revolutionize the traditional fertility process. Their primary goal is to develop innovative therapies that enhance the quality of life for women. In an often underserved therapeutic area, Gameto is committed to addressing the limited treatment options and complications to improve and modernize the entire female reproductive journey.
Gameto has established a platform for generating female reproductive cell lines. Their approach involves the strategic use of proprietary transcription factors to reprogram human induced pluripotent stem cells (hiPSCs) into engineered ovarian and endometrium cell lines. These engineered cells closely mimic the functions of natural endogenous cells, including the production and response to hormones.
One of the significant issues in the realm of female reproductive health is the inadequacy of current hormone replacement methods. Traditional hormone replacement therapies provide hormones at fixed daily doses, failing to deliver personalized and physiologically-based hormone delivery. Recognizing this challenge, Gameto has introduced an innovative implant designed to combat ovarian decline effectively.
This implant consists of an engineered ovarian support cell, an extracellular matrix substrate, and a delivery apparatus. These components work synergistically to provide a more tailored and precise approach to hormone replacement, offering a potential breakthrough in addressing ovarian decline.
Gameto’s dedicated team of cellular engineers is harnessing this platform to advance a diverse portfolio of cellular therapeutics specifically targeted at addressing various female reproductive diseases. Their flagship program, Fertilo, focuses on improving in vitro fertilization (IVF) and egg freezing, with the aim of streamlining the processes, enhancing safety, and increasing effectiveness. Additionally, Gameto’s platform enables the development of an organoid of the female reproductive system, known as Deovo, as well as a cell-based therapeutic called Ameno, which seeks to mitigate the health consequences associated with primary ovarian insufficiency and menopause.
Gameto’s commitment to scientific excellence and innovative solutions positions them at the forefront of reshaping female reproductive healthcare, with the potential to make a significant impact on the lives of countless women.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
